Antengene doses first patient in pivotal Phase III gastric trial
Biotechnology company Antengene Corporation dosed the first patient in its Phase III CLINCH 3 trial evaluating antibody drug conjugate ATG 022 for treating advanced gastric or gastroesophageal junction adenocarcinoma
SHANGHAI and HONG KONG, Sept. 21, 2026 /PRNewswire/ -- Antengene Corporation Limited announced the first patient was administered the investigational drug in the pivotal Phase III CLINCH-3 study of ATG-022 in China. ATG-022 is an ADC targeting CLDN18.2 for advanced gastric or gastroesophageal junction adenocarcinoma. Antengene previously received Breakthrough Therapy Designation for ATG-022 by China's NMPA, expediting regulatory processes.
The CLINCH-3 study, led by Prof. Lin Shen, will compare ATG-022 to standard treatment for patients with CLDN18.2+ advanced gastric or gastroesophageal junction adenocarcinoma. Initial trial data from Phase I/II studies showed ATG-022 had robust efficacy and tolerability.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
